耐高血压慢性病的药物基因组学引导精确疗法:一个前性队列研究
Kidney & blood pressure research
|December 9, 2025
概括
药物基因组学 (PGx) 导向治疗显著改善了血压控制,并减少了慢性病 (CKD) 和耐药高血压 (RH) 患者的不良事件. 这种精准医学方法还有助于随着时间的推移保持功能.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
背景情况:
- 在慢性病 (CKD) 患者中,治疗耐药高血压 (RH) 是复杂的.
- 药物基因组学 (PGx) 在优化该群体治疗中的作用尚未得到充分证实.
研究的目的:
- 评估PGx指导精度疗法在CKD患者中控制血压 (BP) 的有效性.
- 评估对药物优化,安全性和功能保护的影响.
主要方法:
- 一项前性队列研究,涉及65名CKD患有RH的患者.
- 随机划分为经验药物组 (n=22) 和PGx引导组 (n=43).
- PGx组接受了21种抗高血压药物的基因测试治疗;经验组接受了标准护理. 主要结果:BP在24个月实现目标.
主要成果:
- PGx组在早期 (0.5个月) 显示出显著更高的缩血压目标率,并在3个月和24个月后显示出明显更高的腹血压目标率.
- 导向PGx治疗导致不良事件减少41%,并减少了需要4-5种药物组合的需要.
- 基因测试发现对ARBs和CCBs的高敏感性,以及对ACEI的低效率. 功能下降 (eGFR) 在PGx组显着较低.
结论:
- 在PGx引导的精密疗法迅速改善血压控制,减少多药性和不良事件在CKD患者的RH.
- 这种方法表明对功能有保护作用,延缓衰退.
- 这项研究为东亚人口的CKD与RH个性化治疗提供了宝贵的见解.
相关概念视频
01:28Chronic Kidney Disease III: Interprofessional Care
323
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
323
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
196
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
196
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
333
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
333
01:25Chronic Kidney Disease I: Introduction
545
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
545
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
174
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
174
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
888
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888